Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.42 |
| ▸ | IKBKB | O14920 | 6/20 | 0.36 |
| ▸ | CHUK | O15111 | 5/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.34 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.32 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21049576 | 0.77 | DPP4 (0.46) | DPP4DPP8DYRK1A | |
| SCHEMBL10673703 | 0.76 | DPP4 (0.49) | DPP4DPP8GDADYRK1A | |
| SCHEMBL13676395 | 0.74 | DPP4 (0.44) | DPP4DPP8GDADYRK1A | |
| SCHEMBL22349064 | 0.71 | DPP4 (0.42) | DPP4DPP8DYRK1A | |
| SCHEMBL27051515 | 0.71 | DPP4 (0.42) | DPP4DPP8DYRK1A | |
| SCHEMBL25669260 | 0.71 | LMNA (0.41) | DPP4IKBKBCHUKCDK2PLK1 | |
| SCHEMBL21986846 | 0.70 | DPP4 (0.51) | DPP4DPP8 | |
| SCHEMBL4724897 | 0.69 | DPP4 (0.50) | DPP4DPP8GDA | |
| SCHEMBL21986867 | 0.69 | KDM4E (0.40) | DPP4DPP8DYRK1A | |
| Hydrochloric Acid SCHEMBL21986831 | 0.69 | DPP4 (0.65) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | KRAS, NRAS, HRAS | DPP4 3453/4885DPP8 3283/4885IKBKB 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.